Gene Therapy Pioneer Bluebird Bio Plans Bold New Future Under New Ownership
Bluebird Bio, a leader in gene therapy, has been acquired by Carlyle Group and SK Capital Partners. The acquisition offers shareholders a £3.00 per share cash payout, potentially reaching £9.84 based on performance. Facing financial challenges, this deal provides Bluebird with the
